D. Boral Capital Maintains Buy on Immunic, Maintains $17 Price Target

Benzinga · 01/07 13:10
D. Boral Capital analyst Jason Kolbert maintains Immunic (NASDAQ:IMUX) with a Buy and maintains $17 price target.